Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2014 1
2015 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.
Samocha-Bonet D, Wong O, Synnott EL, Piyaratna N, Douglas A, Gribble FM, Holst JJ, Chisholm DJ, Greenfield JR. Samocha-Bonet D, et al. J Nutr. 2011 Jul;141(7):1233-8. doi: 10.3945/jn.111.139824. Epub 2011 May 18. J Nutr. 2011. PMID: 21593352 Free PMC article. Clinical Trial.
Impaired glucagon-like peptide (GLP-1) secretion or response may contribute to ineffective insulin release in type 2 diabetes. ...These findings suggest that glutamine may be a novel agent for stimulating GLP-1 concentration …
Impaired glucagon-like peptide (GLP-1) secretion or response may contribute to ineffective insulin release in type 2 …
L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients.
Samocha-Bonet D, Chisholm DJ, Holst JJ, Greenfield JR. Samocha-Bonet D, et al. Nutrients. 2015 Mar 24;7(4):2101-8. doi: 10.3390/nu7042101. Nutrients. 2015. PMID: 25811109 Free PMC article. Clinical Trial.
L-glutamine triggers glucagon-like peptide-1 (GLP-1) release from L cells in vitro and when ingested pre-meal, decreases postprandial glycaemia and increases circulating insulin and GLP-1 in type 2 di …
L-glutamine triggers glucagon-like peptide-1 (GLP-1) release from L cells in vitro and when …
Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study.
Samocha-Bonet D, Chisholm DJ, Gribble FM, Coster AC, Carpenter KH, Jones GR, Holst JJ, Greenfield JR. Samocha-Bonet D, et al. PLoS One. 2014 Nov 20;9(11):e113366. doi: 10.1371/journal.pone.0113366. eCollection 2014. PLoS One. 2014. PMID: 25412338 Free PMC article. Clinical Trial.
BACKGROUND AND AIMS: L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 …
BACKGROUND AND AIMS: L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administer …
Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetes.
Chang J, Wu T, Greenfield JR, Samocha-Bonet D, Horowitz M, Rayner CK. Chang J, et al. Diabetes Care. 2013 Aug;36(8):2262-5. doi: 10.2337/dc12-1663. Epub 2013 Apr 5. Diabetes Care. 2013. PMID: 23564914 Free PMC article. Clinical Trial.

Ten patients with type 2 diabetes mellitus (T2DM) were also studied with 15 g glutamine or saline. RESULTS: ID glutamine stimulated glucagon-like peptide 1 (GLP-1; healthy: P < 0.05; T2DM: P &l

…
Ten patients with type 2 diabetes mellitus (T2DM) were also studied with 15 g glutamine or saline. RESULT …